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Abstract
Background—The current consensus definition of septic shock requires hypotension after
adequate fluid challenge or vasopressor requirement. Some patients with septic shock present with
hypotension and hyperlactatemia >2mM/L (tissue dysoxic shock), while others have hypotension
alone with normal lactate (vasoplegic shock).
Objective—To determine differences in outcomes of patients with tissue dysoxic versus
vasoplegic septic shock.
Methods—Pre-planned secondary analysis of a large, multi-center randomized control trial.
Inclusion criteria were suspected infection, 2 or more systemic inflammatory response criteria, and
systolic blood pressure <90 mmHg after a fluid bolus. Patients were categorized by presence of
vasoplegic or tissue dysoxic shock. Demographics and sequential organ failure assessment
(SOFA) scores were evaluated between the groups. The primary outcome was in-hospital
mortality.
Results—A total of 247 patients were included, 90 patients with vasoplegic shock and 157 with
tissue dysoxic shock. There were no significant differences in age, race, or gender between the
vasoplegic and tissue dysoxic shock groups. The group with vasoplegic shock had a lower initial
SOFA score than did the group with tissue dysoxic shock (5.5 vs. 7.0 points, p=0.0002). The
primary outcome of in-hospital mortality occurred in 8/90 (9%) of patients with vasoplegic shock
compared to 41/157 (26%) in the group with tissue dysoxic shock (proportion difference 17%,
95% CI 7–26%, p<0.0001; log rank test p = 0.02). After adjusting for confounders, tissue dysoxic
shock remained an independent predictor of in-hospital mortality.
Conclusion—In this analysis of patients with septic shock we found a significant difference in
in-hospital mortality between patients with vasoplegic versus tissue dysoxic septic shock. These
findings suggest a need to consider these differences when designing future studies of septic shock
therapies.
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Sepsis is the tenth leading cause of death in the United States (US) with mortality rates for
severe sepsis estimated to be 30% or higher.1 Severe sepsis has also been estimated to be the
primary cause for at least 500,000 emergency department (ED) visits annually in the US,
with average ED stay times of almost 5 hours.2 The current consensus definition of overt
septic shock requires suspicion of infection and systemic inflammation associated with
persistent hypotension after adequate fluid challenge or a vasopressor requirement.3
Furthermore, hyperlactatemia has been shown to be a predictor of mortality in sepsis that is
independent of organ failure and shock, with even modest elevations in lactate (2–4 mmol/
L) having an impact on clinical outcomes.4,5 The objective of this study was to determine if
there are differences in clinical characteristics and outcomes among patients with vasoplegic
septic shock, defined as overt shock and a normal lactate, as compared to patients with tissue
dysoxic septic shock, defined as overt shock and an elevated lactate >2 mM/L.
Methods
Study Design
We conducted a secondary analysis of a recently completed, large, multi-center randomized
control trial.6 The objective of the trial was to evaluate the non-inferiority of lactate
clearance versus central oxygen saturation (ScvO2) as a marker of adequate oxygen delivery
during early quantitative resuscitation of septic patients in the ED.
The methodology of the trial was previously reported.6 In short, the trial was conducted at
Carolinas Medical Center, Charlotte, NC, Beth Israel Deaconess Medical Center, Boston,
MA, and Cooper University Hospital, Camden, NJ and occurred between January 2007 and
January 2009. The Institutional Review Board at each institution (090602A) approved the
study, and all participants or their surrogate provided written informed consent. The trial
was registered on Clinicatrials.gov identifier NCT00372502.
Patients presenting to participating EDs with septic shock were consecutively enrolled or
were eligible for enrollment if they were older than 17 years old, had confirmed or suspected
infection, two or more systemic inflammatory response criteria, and systolic blood pressure
<90 mmHg after a 20mL/kg rapid volume challenge or a whole blood lactate concentration
of > 4 mmol/L. Patients were excluded from participation if they were pregnant, had any
primary diagnosis other than sepsis, an expected surgical requirement within six hours of
diagnosis, an absolute contraindication to chest or neck central venous catheterization,
cardiopulmonary resuscitation, or advanced directive orders that would conflict with the
study procedure. Once enrolled, patients were randomized to 1 of 2 study groups. While in
the ED, each group had a structured quantitative resuscitation protocol, which has been
previously described and published. 6 The ScvO2 group (N=150) was resuscitated by
directing therapy required to meet threshold values of central venous pressure, mean arterial
pressure, and central venous oxygen saturation (ScvO2). The lactate clearance group
(N=150) had similarly targeted goals in central venous pressure, mean arterial pressure, and
then lactate clearance (decrease in lactate of at least 10% over at least 2 hours) instead of
ScvO2 as a measure for adequate oxygen delivery. Protocols were followed until all
endpoints were met or a maximum time of 6 hours was reached. The results of this study
confirmed the primary hypothesis of non-inferiority, with a 6% (95% confidence intervals
−3 to 14%) in-hospital mortality difference between the two study groups.6 A total of 300
patients were randomized, 53 of whom demonstrated an elevated lactate and normotension,
and were therefore excluded from the present analysis. This group of patients has been
analyzed and the results published previously7, and were outside the scope of the current
analysis given the focus on patients with hypotension in sepsis.
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For the present study, we categorized patients enrolled in the trial into one of two groups,
vasoplegic shock or tissue dysoxic shock, as previously defined. Patient demographics and
clinical characteristics were evaluated between the two groups using t-tests, Mann-Whitney-
U, and chi-squared tests, as appropriate. The primary outcome of in-hospital mortality was
evaluated using proportion differences and Kaplan-Meier curve with log rank test. In order
to assess for potential confounding, we conducted a logistic regression model using in-
hospital mortality as the dependent variable. Candidate variables were chosen based on
known predictors of mortality, such as age and degree of organ dysfunction, and those
variables found to be different between groups in the bivariate analysis, and maintained in
the multivariate model if p < 0.10 to maintain the event to independent variable ratio of
approximately 8–10:1.8 The model was refined using reverse stepwise elimination. Model
fit was determined using Hosmer and Lomeshow’s goodness of fit test. All statistical tests
were two sided with p<0.05 considered significant. Data were analyzed using STATA (10.0,
StataCorp, College Station, TX) or StatsDirect statistical software (StatsDirect 2.7.7,
Cheshire, England).
Results
A total of 247 patients were included in this study. 90 (36%) patients met criteria for
vasoplegic shock versus 157 (64%) with tissue dysoxic shock. Patient demographics and
initial clinical characteristics are shown in Table 1. There were no significant differences in
demographics between the vasoplegic and tissue dysoxic shock groups. The group with
vasoplegic shock had a lower initial SOFA score (5.5 points) than the group with tissue
dysoxic shock (7.0 points) (p=0.0002).
The primary outcome of in-hospital mortality occurred in 49/247 (20%) patients, including
8/90 (9%, 95% CI 4 to 17%) in the vasoplegic shock compared to 41/157 (26%, 95% CI 19
to 34%) in the tissue dysoxic shock group (proportion difference 17%, 95% CI 7–26%,
p<0.0001). Figure 1 shows survival to hospital discharge curve for the two groups using a
Kaplan-Meier format. A significant difference in survival between the two groups was noted
(log rank test p = 0.02.) Additionally, we found significant differences in ICU and hospital
length of stay and multiple organ failure between the groups (Table 3).
To attempt to control for potential confounding, we developed a logistic regression model
using in-hospital mortality as the dependent variable. The final model including age, total
Sequential Organ Failure Assessment score at enrollment, treatment with norepinephrine
versus other vasopressors, and shock type (vasoplegic versus tissue dysoxic shock).
Increasing age and SOFA score were associated with adverse outcome, while choice of
norepinephrine versus other vasopressors was associated with improved outcomes in the
multivariate model. The adjusted odds ratio to predict in-hospital mortality for tissue
dysoxic was 3.0 (95% CI 1.3–7.2). The final model demonstrate goodness of fit by the
method of Hosmer and Lomeshow (p = 0.83).
Discussion
In this study we sought to evaluate the differences in outcome for patients with vasoplegic
shock and tissue dysoxic shock. Our results indicate a significant difference in mortality
between the two groups and that the presence of tissue dysoxic shock is an independent
predictor of in-hospital mortality, even after accounting for potential confounding variables
between cohorts. These results highlight the importance of potentially considering these
subgroups of shock differently, particularly during enrollment into clinical trials where
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homogeneous populations are necessary to decrease the likelihood of random error and
maintain the power to detect differences between study groups.
In this study, we evaluated only patients with septic shock by consensus definition and
categorized those patients as having a normal lactate or an elevated lactate. In clinical
practice, patients with persistent hypotension would be treated similarly, with fluids,
vasopressors and inotropic agents, regardless if lactate levels were elevated or normal. Thus
the implications of our results for clinicians are more prognostic than therapy changing.
However, for the clinical trialist, these results could potentially impact the design of
inclusion criteria for trials and may serve to ensure less heterogeneity in septic shock
populations.
Previous authors have questioned if patients with sepsis-induced hypotension and a normal
lactate should be considered septic shock.9 Hernandez et al examined the addition of
hyperlactatemia to the consensus definition of septic shock citing significant differences in
mortality between septic shock patients without an elevated lactate compared to those with
an elevated lactate (7.7% and 42.9%, respectively). These authors went on the question if
hypotension without lactate elevation should even be considered septic shock. In follow-up
of their initial study, Hernandez and colleagues evaluated the outcomes and microcirculatory
profiles of septic shock patients with and without hyperlactatemia. They again found
significant differences in mortality and microcirculatory blood flow in patients with sepsis-
induced hypotension and a normal lactate when compared to those with an elevated
lactate.10
Our findings confirm these findings and suggest a differential prognosis for patients with
biochemical evidence of tissue dysoxia as opposed to just vasoplegia without evidence of
tissue dysoxia. In the previous study by Hernandez et al, patients were evaluated with serial
lactates during the pre-ICU and ICU resuscitation periods, and patients with any abnormal
lactate measurement during that time were included in the hyperlactatemia subgroup.9 Our
study grouped Emergency Department patients based on initial lactate levels and further
shows inherent differences apparent on presentation, despite disease course or resuscitation
efforts.
Additionally, previous research by Puskarich et al.7 evaluated the outcomes of the varying
presentations of septic shock. In that study, cryptic shock (suspected infection with a lactate
greater than 4 mmol/L and normotension) and overt shock (suspected infection and
persistent hypotension) had similar in-hospital mortality rates of 20% and 19%, respectively.
Our study extends these findings to further show that there are significant differences within
the overt shock group when incorporating lactate as a variable.
Our study does have some important limitations. The initial study took place at experienced
hospitals that perform high volumes of acute sepsis resuscitations and thus have resources
that may not be available at other hospitals, so the results of this study may not be
generalizable. Also, patients were placed into 1 of 2 treatment groups with different
protocols in the initial study. The ScvO2 treatment group’s protocol did not target lactate
clearance, which has been associated with worse outcomes versus lactate non-clearance and
discordance from ScvO2 optimization.11 However, both treatment groups had protocols with
similar goals and outcomes and both the vasoplegic and tissue dysoxic shock groups had
similar rates of achieving their pre-defined resuscitation goals (Table 2), mitigating this
potential concern. Furthermore, when added to the multivariate model, treatment arm did not
impact the results of our study. Finally our study can only draw associations and cannot
show cause and effect.
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In this analysis, we found a significant difference in in-hospital mortality between
vasoplegic and tissue dysoxic septic shock groups. These findings suggest a need to consider
such outcomes when designing future studies of septic shock therapies.
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Table 1
Patient demographics and clinical characteristics
Variable VS group (N=90) TDS group (N=157) P value
Age * 58 (47–71) 61 (51–93) 0.21
Sex (%)
 Male 47 (52) 90 (57) 0.51
 Female 43 (48) 67 (43)
Race (%)
 Caucasian 53 (59) 83 (53) 0.43
 Black American 24 (27) 61 (39)
 Hispanic 10 (11) 11 (7)
 Other 3 (3) 2 (1)
Disease Severity *‡
 SOFA score 5.5 (4–7) 7.0 (4–10) 0.0007
Comorbidities (%)
 Diabetes mellitus 18 (20) 58 (34) 0.009
 Hypertension 44 (49) 90 (57) 0.25
 Congestive heart failure 17 (19) 20 (13) 0.26
 Peripheral vascular disease 7 (8) 17 (11) 0.58
 History of MI 11 (12) 13 (8) 0.43
 Chronic steroid use 10 (11) 21 (13) 0.75
 Human immunodeficiency virus 9 (10) 14 (9) 0.96
 End stage renal disease 4 (4) 15 (10) 0.23
 Chronic obstructive pulmonary disease 13 (14) 28 (18) 0.61
Suspected Source of Infection
 Pneumonia 32 (36) 60 (38) 0.78
 Urinary tract 26 (29) 40 (25) 0.77
 Intra-abdominal 7 (8) 23 (15) 0.16
 Vascular line 1 (1) 9 (6) 0.02
 Skin/Soft tissue 11 (12) 17 (11) 0.90
 Unknown 11 (12) 7 (4) 0.045




 Disease severity scores calculated at time of enrollment
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Table 2
Administered treatment and resuscitation endpoints
VS group (N=90) TDS group (N=157) P value
Interventions
 Total fluids in ED (L)* 4.5 (3.1–6) 4.1 (3–5.3) 0.23
 Steroids in 6 hours (%) 16 (18) 23 (15) 0.64
 Vasopressors (%)
  Norepinephrine 43 (48) 99 (63) 0.03
  Dopamine 18 (20) 30 (19) >0.99
Resuscitation Goals Achieved After Interventions
 Central Venous Pressure 82 (91) 136 (87) 0.40
 Mean Arterial Pressure 87 (97) 147 (94) 0.32
Abbreviations: VS = Vasoplegic Shock; TDS = Tissue Dysoxic Shock;
*
Median (IQR)
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Table 3
Patient Outcomes
Variable VS group (N=90) TDS group (N=157) P value
In-hospital mortality (%) + 8 (9) 41 (26) 0.002
Length of Stay*
 ICU 2.6 (1.5–5) 4 (1.9–8.2) 0.009
 Hospital 7 (5–10) 9 (5.1–17) 0.042
Hospital complications (%)
 Multiple organ failure 10 (11) 44 (28) 0.003
 Care withdrawn 6 (7) 20 (13) 0.200
Abbreviations: VS = Vasoplegic Shock; TDS = Tissue Dysoxic Shock;
+
 Primary study end point
*
Median (IQR)
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